Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 79

2.

Long-term perspective on the prevalent-cohort biases in studies of human immunodeficiency virus progression.

Alcabes P, Pezzotti P, Phillips AN, Rezza G, Vlahov D.

Am J Epidemiol. 1997 Oct 1;146(7):543-51.

PMID:
9326431
3.

Changes in the uptake of antiretroviral therapy and survival in people with known duration of HIV infection in Europe: results from CASCADE.

CASCADE (Concerted Action on SeroConversion to AIDS and Death in Europe) Collaboration.

HIV Med. 2000 Oct;1(4):224-31.

4.

Is the time from HIV seroconversion a determinant of the risk of AIDS after adjustment for updated CD4 cell counts?

Concerted Action on SeroConversion to AIDS and Death in Europe (CASCADE Collaboration).

J Acquir Immune Defic Syndr. 2001 Oct 1;28(2):158-65.

PMID:
11588510
6.

Estimating the effect of antiretroviral treatment during HIV seroconversion: impact of confounding in observational data.

Clements M, Law M, Pedersen C, Kaldor J; CASCADE Collaboration.

HIV Med. 2003 Oct;4(4):332-7.

7.
8.

Changes over time in post-seroconversion CD4 cell counts in the Italian HIV-Seroconversion Study: 1985-2002.

Dorrucci M, Phillips AN, Longo B, Rezza G; Italian Seroconversion Study.

AIDS. 2005 Feb 18;19(3):331-5.

PMID:
15718844
9.

HIV-1 infection in rural Africa: is there a difference in median time to AIDS and survival compared with that in industrialized countries?

Morgan D, Mahe C, Mayanja B, Okongo JM, Lubega R, Whitworth JA.

AIDS. 2002 Mar 8;16(4):597-603.

PMID:
11873003
10.
11.

[Determination of the beginning of follow-up in longitudinal studies applied to HIV infections].

Pérez-Hoyos S, Ferreros I, Hurtado I, del Amo J, Hernández-Aguado I.

Rev Esp Salud Publica. 2004 Mar-Apr;78(2):215-27. Spanish.

12.

Factors influencing HIV progression in a seroconverter cohort in Madrid from 1985 to 1999.

del Amo J, del Romero J, Barrasa A, Pérez-Hoyos S, Rodríguez C, Díez M, García S, Soriano V, Castilla J; Grupo de Seroconvertores de la Comunidad de Madrid.

Sex Transm Infect. 2002 Aug;78(4):255-60.

13.
14.

Response to highly active antiretroviral therapy according to duration of HIV infection.

Pezzotti P, Pappagallo M, Phillips AN, Boros S, Valdarchi C, Sinicco A, Zaccarelli M, Rezza G; Italian Seroconversion Study.

J Acquir Immune Defic Syndr. 2001 Apr 15;26(5):473-9.

PMID:
11391168
15.

CD4+ guided antiretroviral treatment interruption in HIV infection: a meta-analysis.

Seminari E, De Silvestri A, Boschi A, Tinelli C.

AIDS Rev. 2008 Oct-Dec;10(4):236-44.

PMID:
19092979
16.

Trends in AIDS and mortality in HIV-infected subjects with hemophilia from 1985 to 2003: the competing risks for death between AIDS and liver disease.

del Amo J, Pérez-Hoyos S, Moreno A, Quintana M, Ruiz I, Cisneros JM, Ferreros I, González C, García de Olalla P, Pérez R, Hernández I.

J Acquir Immune Defic Syndr. 2006 Apr 15;41(5):624-31.

PMID:
16652037
17.

Determinants of HIV progression and assessment of the optimal time to initiate highly active antiretroviral therapy: PISCIS Cohort (Spain).

Jaén A, Esteve A, Miró JM, Tural C, Montoliu A, Ferrer E, Riera M, Segura F, Force L, Sued O, Vilaró J, Garcia I, Masabeu A, Altès J, Coltet B, Podzamczer D, Murillas J, Navarro G, Gatell JM, Casabona J; PISCIS Study Group.

J Acquir Immune Defic Syndr. 2008 Feb 1;47(2):212-20.

PMID:
18297762
18.

Evaluating the effect of year of seroconversion on HIV progression in cohort studies. Italian Seroconversion Study.

Cozzi Lepri A, Phillips AN, Pezzotti P, Mocroft A, Sabin CA, Porter K, Rezza G.

AIDS. 1998 Jul 30;12(11):1353-60.

PMID:
9708416
19.

Estimating patterns of CD4 lymphocyte decline using data from a prevalent cohort of HIV infected individuals.

Vittinghoff E, Malani HM, Jewell NP.

Stat Med. 1994 Jun 15;13(11):1101-18.

PMID:
7916470
20.

Determinants of survival in HIV-positive patients.

Baillargeon J, Borucki M, Black SA, Dunn K.

Int J STD AIDS. 1999 Jan;10(1):22-7.

PMID:
10215125

Supplemental Content

Support Center